Anjana Pillai to Treatment Outcome
This is a "connection" page, showing publications Anjana Pillai has written about Treatment Outcome.
Connection Strength
0.483
-
Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin. Aliment Pharmacol Ther. 2017 06; 45(11):1427-1432.
Score: 0.059
-
Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience. Am J Gastroenterol. 2016 Feb; 111(2):250-60.
Score: 0.054
-
Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C. Transplant Proc. 2010 Nov; 42(9):3647-51.
Score: 0.038
-
Non-alcoholic fatty liver disease: is bariatric surgery the answer? Clin Liver Dis. 2009 Nov; 13(4):689-710.
Score: 0.035
-
Modified Radiation Lobectomy Strategy of Radioembolization for Right-Sided Unresectable Primary Liver Tumors. J Vasc Interv Radiol. 2024 Jul; 35(7):989-997.e2.
Score: 0.024
-
Association between bridging therapy and posttransplant outcomes in patients with HCC within Milan criteria: A systematic review and meta-analysis. Liver Transpl. 2024 Jun 01; 30(6):595-606.
Score: 0.024
-
Tumor Size and Watershed Area Correlate with Incomplete Treatment and Tumor Progression after Selective Radioembolization for Hepatocellular Carcinoma. J Vasc Interv Radiol. 2024 May; 35(5):712-721.e3.
Score: 0.024
-
Selective internal radiation therapy using yttrium-90 microspheres for treatment of localized and locally advanced intrahepatic cholangiocarcinoma. Eur Radiol. 2024 Apr; 34(4):2374-2383.
Score: 0.023
-
Segmental Yttrium-90 Radioembolization Using Glass Microspheres Greater than 400 Gray for the Treatment of Intrahepatic Cholangiocarcinoma: A Preliminary Experience. J Vasc Interv Radiol. 2023 11; 34(11):1970-1976.e1.
Score: 0.023
-
Living donor liver transplantation: A multi-disciplinary collaboration towards growth, consensus, and a change in culture. Clin Transplant. 2023 07; 37(7):e14953.
Score: 0.022
-
A survey of transplant providers regarding attitudes, barriers, and facilitators to living donor liver transplantation in the United States. Clin Transplant. 2023 07; 37(7):e14967.
Score: 0.022
-
Yttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as the First-Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma. J Vasc Interv Radiol. 2023 04; 34(4):702-709.
Score: 0.022
-
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. J Immunother Cancer. 2022 06; 10(6).
Score: 0.021
-
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatol Commun. 2022 07; 6(7):1776-1785.
Score: 0.021
-
Living Donor Liver Transplantation in the United States: Evolution of Frequency, Outcomes, Center Volumes, and Factors Associated With Outcomes. Liver Transpl. 2021 07; 27(7):1019-1031.
Score: 0.020
-
Safety and efficacy of repeat Y90 radioembolization to the same hepatic arterial territory. Br J Radiol. 2021 Mar 01; 94(1119):20200752.
Score: 0.019
-
Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology. 2019 11; 157(5):1253-1263.e2.
Score: 0.017
-
Liver Transplantation in the Obese Cirrhotic Patient. Transplantation. 2017 10; 101(10):2288-2296.
Score: 0.015